2022.10.06
On October 6, 2022, AIM Vaccine Co., Ltd. (“AIM Vaccine”, with stock code 06660.HK), the largest full-chain private vaccine group in China, issued 9,714,000 H shares globally (excluding over-allotment options) and was listed on the Main Board of the HKEx (the “Project”).
AIM Vaccine is the largest full-chain private vaccine group in China. It ranks second in China’s vaccine market and first among private vaccine companies in terms of lot release volume (excluding that of COVID-19 vaccines) in 2021. As a major vaccine company in China, AIM Vaccine has businesses covering the whole value chain from R&D, manufacturing to commercialization. Currently, products available for sale include a recombinant hepatitis B vaccine (hansenula polymorpha), a rabies vaccine (Vero Cell) for human use, a freeze-dried, hepatitis A vaccine (human diploid cell), an inactivated, mumps vaccine, a live hemorrhagic fever with renal syndrome bivalent vaccine (Vero cell) and an ACYW135 meningococcal polysaccharide vaccine (MPSV4). AIM Vaccine is the only Chinese vaccine company possessing all five authenticated human vaccine platform technologies worldwide, including bacterial, viral, genetic engineering, integrated and mRNA vaccine platform technologies. As to each technical platform, AIM Vaccine has at least one vaccine product that has been commercialized or is currently under development.
Under the adverse influence of the COVID-19 epidemic and the great uncertainty of the capital market in Hong Kong, JunHe acted as the Chinese legal counsel to the joint sponsor and the underwriter in the Project. JunHe’s team assisted the joint sponsor in conducting multiple rounds of legal due diligence and many third-party due diligence investigations. They reviewed and revised the prospectus, the application and the offering documents related to the issuance, the listing of the H shares and their full circulation, issued Chinese legal opinions, and replied to feedback from the regulatory authorities. JunHe was unanimously recognized by the client and other intermediaries for its consistent, efficient and rigorous working style as well as its meticulous and professional services.
The Project was led by Mr. TAO, Xudong and Mr. NIU, Yuandong. It was primarily undertaken by Mr. NIU, Yuandong, and internally reviewed by Mr. LI, Zhi.
